SavedAdd your journal

Journals / Haydarpaşa Numune Medical Journal / 2021 / Cilt: 61 - Sayı: 2

Comparison of Ibuprofen Protocols in the Pharmacological Treatment of Patent Ductus Arteriosus

Gülendam KOÇAK
İpek AKMAN
Yeşim CŞKUN
Pages
183–188
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Methods: The study was conducted with 64 preterm infants in neonatal intensive care unit with gestational age

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Ibuprofen (IBU) is an effective agent for the pharmacological treatment of patent ductus arteriosus (PDA) in premature infants.
📊
Key Findings & Data:In this study, we compared the efficacy and complications of intravenous bolus therapy (IVBT) and con- tinuous intravenous infusion therapy (CIVIT) for the treatment of PDA.
💡
Conclusion & Impact:Methods: The study was conducted with 64 preterm infants in neonatal intensive care unit with gestational age
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Ibuprofen (IBU) is an effective agent for the pharmacological treatment of patent ductus arteriosus (PDA) in premature infants. In this study, we compared the efficacy and complications of intravenous bolus therapy (IVBT) and con- tinuous intravenous infusion therapy (CIVIT) for the treatment of PDA. Methods: The study was conducted with 64 preterm infants in neonatal intensive care unit with gestational age

🔖

Cite This Article

KOÇAK, G., AKMAN, İ., CŞKUN, Y. (2022). Comparison of Ibuprofen Protocols in the Pharmacological Treatment of Patent Ductus Arteriosus. Haydarpaşa Numune Medical Journal, Cilt: 61 - Sayı: 2, 183–188. https://ajindex.com/articles/535915

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010;125:1020–30
  2. Mezu-Ndubuisi OJ, Agarwal G, Raghavan A, Pham JT, Ohler KH, Maheshwari A. Patent ductus arteriosus in premature neonates. Drugs 2012;72:907–16
  3. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006;117:1113–21
  4. Dani C, Poggi C, Mosca F, Schena F, Lista G, Ramenghi L, et al. Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: Study protocol for a randomized control trial. Trials 2016;17:182
  5. Raval MV, Laughon MM, Bose CL, Phillips JD. Patent ductus arteriosus ligation in premature infants: Who really benefits, and at what cost? J Pediatr Surg 2007;42:69–75
  6. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev 2015;2:CD003481
  7. Gournay V, Roze JC, Kuster A, Daoud P, Cambonie G, Hascoet JM, et al. Prophylactic ibuprofen versus placebo in very pre- mature infants: A randomised, double-blind, placebo-con- trolled trial. Lancet 2004;364:1939–44
  8. Lago P, Salvadori S, Opocher F, Ricato S, Chiandetti L, Frigo AC. Continuous infusion of ibuprofen for treatment of patent duc- tus arteriosus in very low birth weight infants. Neonatology 2014;105:46–54
  9. Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G, et al. Dose-finding study of ibuprofen in patent ductus arte- riosus using the continual reassessment method. J Clin Pharm Ther 2005;30:121–32
  10. Hirt D, Van Overmeire B, Treluyer JM, Langhendries JP, Mar- guglio A, Eisinger MJ, et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacody- namic study. Br J Clin Pharmacol 2008;65:629–36
  11. Dani C, Vangi V, Bertini G, Pratesi S, Lori I, Favelli F, et al. High- dose ibuprofen for patent ductus arteriosus in extremely preterm infants: A randomized controlled study. Clin Pharma- col Ther 2012;91:590–6
  12. Guignard JP. The adverse renal effects of prostaglandin-syn- thesis inhibitors in the newborn rabbit. Semin Perinatol 2002;26:398–405
  13. Vieux R, Desandes R, Boubred F, Semama D, Guillemin F, Buchweiller MC, et al. Ibuprofen in very preterm infants im- pairs renal f